Massachusetts-based biotechnology firm Biogen and its Tokyo-based partner Eisai are seeking a speedy approval from the U.S. Food and Drug Administration for a second Alzheimer’s disease drug, lecanemab.
Alzheimer’s disease is the holy grail of pharmaceutical research, and a team of physicians published results showing that they may have found the key to actually improving cognition in patients with early-stage dementia.
A study published in the Journal of the American Medical Association shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said.
Many of the same things people should do for a healthy heart – such as exercising, eating well and avoiding cigarettes – can also help protect the brain from cognitive decline and dementia, according to the American Heart Association and the American Stroke Association.
One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.